Topical Spironolactone for Hair Loss: Four Trial Findings

The six-month gel study reported improvement in both groups

A 2025 paper¹ reported 80 women, divided between 1% spironolactone gel and 5% minoxidil gel, each used twice daily for six months. Photograph assessments and hair measurements improved within both groups, with no significant between-group difference reported.¹

That result does not prove equivalence. This was a small comparative study without a vehicle-only arm or a prespecified equivalence margin. The spironolactone preparation was made for the study at a university pharmacy department.¹

Contact dermatitis, scaling and irritation were reported, despite the authors describing the effects as tolerable. The paper reported no financial support.¹

The 16-week solution study found little benefit with spironolactone

Another 2025 trial² randomized 45 women aged 23–43, with 15 per group, to 5% spironolactone solution, 1% finasteride solution or 5% minoxidil solution for 16 weeks, twice daily.²

Spironolactone’s average measured density rose from 92.4 to 97.67 hairs/cm², a change that did not reach statistical significance. Minoxidil’s rose from 96.13 to 131.67 hairs/cm². After treatment, density was significantly higher with minoxidil than spironolactone.²

Masked photograph assessors rated 11 of 15 spironolactone participants as having poor improvement. The study was short and reported no funding; serum androgens were not measured.²

The studies cannot rank 1% against 5%

Neither trial directly compared the two spironolactone strengths; duration and vehicle differed.¹²

Both excluded pregnant or breastfeeding women; neither establishes safety for them or absence of systemic effects.¹²

Before comparing percentages on bottles, ask which complete preparation was tested and whether the proposed prescription matches it. Include any other active ingredients in that question.

A compounded product needs its own prescribing discussion

In the US, compounded medicines are not FDA-approved. FDA does not verify their safety, effectiveness or quality before marketing. Compounding can meet individual needs when an approved medicine is unsuitable, but it does not make a preparation interchangeable with a published study product.³

Ask who prepares it, what it contains, how it should be stored and when it should be discarded. Get instructions for side effects and a review date before starting. The FDA advises checking the pharmacy and discussing prescription questions with a healthcare professional.³

Start with the diagnosis and a dated record

The American Academy of Dermatology⁴ recommends a dermatologist’s assessment, because other causes of hair loss can resemble female-pattern thinning. Its treatment guidance describes FDA-approved topical minoxidil separately from prescription pills used for other indications.⁴

Bring previous treatment names and dates, photographs taken under similar lighting, and the reason you stopped each product. Ask how the proposed scalp preparation compares with the options already tried.

“Your Hair Log” in Hair, Everywhere records monthly photographs, recent changes and treatment start dates. Our oral spironolactone prescribing guide addresses the pill discussion separately.